PBAC's latest decision on Baricitinib: Recommended with restriction (2021). Considered for Initial and continuing treatment of adults with severe atopic dermatitis who have failed to achieve an adequate response to topical therapies (topical corticosteroids and/or topical calcineurin inhibitors).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
4
first 2017
Submissions
4
2017 → 2021
Eligible population
Adults with severe atopic dermatitis (PGA score of 4 and EASI score ≥20, or severe AD of face or palm of hand) who have failed to achieve an adequate response to topical corticosteroids and/or topical calcineurin inhibitors.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
ORR
Comparator
dupilumab
ICER note
ICER not stated in the public document. Economic evaluation section appears to be redacted or incomplete in the provided text.
Submission history
Jul 2017: Recommended with restriction · Restricted
Nov 2017: Deferred · Authority Required
Mar 2018: Recommended with restriction · Restricted
Jul 2021: Recommended with restriction · Authority Required